天津医药

• 抗凝专栏 • 上一篇    下一篇

纤溶酶联合利伐沙班治疗下肢深静脉血栓的临床研究

张庆   

  1. 天津市职业病防治院
  • 收稿日期:2013-05-27 修回日期:2013-07-27 出版日期:2013-09-15 发布日期:2013-09-15
  • 通讯作者: 张庆

Treatment of deep venous thrombosis of lower extremities with fibrinolysin and rivaroxaban

Qing ZHANG   

  • Received:2013-05-27 Revised:2013-07-27 Published:2013-09-15 Online:2013-09-15
  • Contact: Qing ZHANG

PDF (PC)

2771

摘要：

 

关键词: 静脉血栓形成, 纤溶酶, 因子Ⅹa, 血液凝固试验, 利伐沙班

Abstract: Objective To observe the effect of the fibrinolysin and rivaroxaban to treat deep venous thrombosis. Methods 63 patients from Janurary, 2010 to August, 2011 were divided into two groups: observation group (n=32) was treated with fibrinolysin 200U/L and rivaroxaban 10mg/d; controll group (n=31) was treated with fibrinolysin 200U/L and Low Molecular Dextran. Fibrinogen, coagulation time, and prothrombin time were tested. Doppler ultrasound was performed to evaluate the effect of thrombolysis. Results There were significant difference bewteen two groups in effect of thrombolysis and fibrinogen. Fibrinolysin and rivaroxaban could have better effect than controll group. There were not significant difference in coagulation time, prothrombin time, and severe bleeding events. Conclusion Fibrinolysin and rivaroxaban could be an effective option for deep venous thrombosis.